BetterInvesting™ Magazine Update on Equifax Inc. (NYSE: EFX) and Neurocrine Bio In. (NASDAQ: NBIX)
March 3, 2026Equifax Inc.’s recent report has investors wondering if the company’s stock is fairly valued. Or is it in the buy range? As such, the Editorial Advisory and Securities Review Committee of BetterInvesting Magazine considers Equifax (NYSE: EFX) as worthy of further study and has named the company its “Stock to Study” for the May 2026 issue for investors’ informational and educational use.
The fundamental data is eye-opening; investors can view Equifax’s sales, earnings, pre-tax profit, return on equity, and more all on one page, courtesy of the National Association of Investors Corp., at: https://ssg.betterinvesting.org/trial/ssgplus/?ticker=EFX.
A full report on Equifax will appear in the May 2026 issue of BetterInvesting Magazine.
The same issue of BetterInvesting Magazine will also include a fundamental review of Neurocrine Bio In. (NASDAQ: NBIX), which the independent Editorial Advisory and Securities Review Committee believes is worthy of further study from an undervalued perspective.
Committee members are Daniel J. Boyle, CFA; Marisa Bradbury, CFA; Philip Keating, CFA; Walter J. Kirchberger, CFA; Anne Nichols, CFA; and Dan Rutter, CFA.
Doron P. Levin, an editor of the magazine, serves as the committee’s chairperson.
Securities mentioned are for study and presented for educational purposes only. They are not to be considered as endorsed or recommended for purchase by NAIC/BetterInvesting. Investors should conduct their own review and analysis of any company of interest using the Stock Selection Guide before making an investment decision.
